Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients-Reference-Cited by-同舟云学术

Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients

Published:2018-05-16 Issue:6 Volume:181 Page:770-781
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Bram Ednersson Susanne¹²,Stenson Martin³²,Stern Mimmie⁴²,Enblad Gunilla⁵,Fagman Henrik¹²,Nilsson-Ehle Herman⁶²,Hasselblom Sverker⁷,Andersson Per-Ola⁴²^ORCID

Affiliation:

1. Department of Pathology; Sahlgrenska University Hospital; Gothenburg Sweden

2. Sahlgrenska Academy at the University of Gothenburg; Gothenburg Sweden

3. Section of Haematology; Department of Medicine; Kungälvs Hospital; Kungälv Sweden

4. Section of Haematology; Department of Medicine; South Älvsborg Hospital; Borås Sweden

5. Department of Immunology, Genetics and Pathology/Experimental and Clinical Oncology; Uppsala University; Uppsala Sweden

6. Section of Haematology and Coagulation; Sahlgrenska University Hospital; Gothenburg Sweden

7. Department of Research, Development and Education; Region Halland; Halmstad Sweden

Funder

ALF Västra Götaland

Cancerfonden

Göteborgs Läkaresällskap

Lions Cancerfond Väst

IngaBritt och Arne Lundbergs Forskningsstiftelse

Cancer and Development Foundation of Borås

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15259/fullpdf

Reference54 articles.

1. Overexpression of ribosomal proteins L4 and L5 and the putative alternative elongation Factor PTI-1 in the doxorubicin resistant human colon cancer cell line LoVoDxR;Bertram;European Journal of Cancer,1998

2. Targeted cancer therapy with ribosome biogenesis inhibitors: a real possibility?;Brighenti;Oncotarget,2015

3. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53;Bywater;Cancer Cell,2012

4. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review;Camicia;Molecular Cancer,2015

5. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte;Coiffier;Blood,2010

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma;Blood Cancer Journal;2023-10-26

2. Proteomic Portrait of Human Lymphoma Reveals Protein Molecular Fingerprint of Disease Specific Subtypes and Progression;Phenomics;2022-12-12

3. Clinical and pathological findings in neurolymphomatosis: Preliminary association with gene expression profiles in sural nerves;Frontiers in Oncology;2022-09-26

4. Sufficient principal component regression for pattern discovery in transcriptomic data;Bioinformatics Advances;2022-01-01

5. Proteomic Landscape of Extracellular Vesicles for Diffuse Large B-Cell Lymphoma Subtyping;International Journal of Molecular Sciences;2021-10-12